🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Dyno team will be at #NeurIPS2023 in New Orleans next week! On December 15th we’ll be at the poster sessions for the MLSB and GenBio Workshops, presenting on the generative models that allow us to optimize our field-leading therapeutic capsids. See you there! 👋

Reflecting on an incredible 2023 at Dyno! This year our team launched two new groundbreaking capsids - Dyno eCap 1 and bCap 1 for delivery to the eye and brain. As we break for our winter shutdown next week, we're looking forward to more groundbreaking science in 2024! 🚀

What a pleasure working with Elliot Hershberg! Thank you for highlighting our origin story and how Dyno is changing the face of gene delivery with our AI-powered platform, our recent product launches, and our horizontal partnership-focused business model. 🚀

On January 24th, Dyno’s CSO and Co-founder Adrian Veres will be joining a powerhouse panel of industry leaders at #PMWC24 to discuss the future challenges and potential of gene therapy as a treatment for rare diseases 🧬Learn more at: pmwcintl.com/program

Dyno is gearing up for the annual conference of the American Society of Gene & Cell Therapy! At #ASGCT2024 we’ll be showing three abstracts and giving a Symposium talk on 5/9 @ 12:15 EST with exclusive previews of the technology we're developing to lead biotech’s AI revolution.

It’s a busy conference season here at Dyno! From May 8-9 we will be at #SynBioBeta2024 to share our recent successes applying AI to design better gene therapies, and discuss how these methods can help patients in an era of rapid technological advancement. Don't miss it!

Dyno’s CEO and Founder Eric Kelsic will be give a fireside chat today at Chardan's 8th Annual Genetic Medicines & Cell Therapy Manufacturing Summit to discuss how next-gen discovery platforms like Dyno’s can support the increasing demand for gene therapy 🧬

Excited for our panel at SynBioBeta this Thursday! Our experts will be discussing what it takes to translate the use of generative AI for real-world therapeutic impact. You can submit your questions for the Q&A portion of the panel here: forms.gle/imdDYGbfe9gduJ… #SynBioBeta2024

Dyno is in Seattle this week for the annual meeting of the Association for Research in Vision and Ophthalmology 👁🧬 We’ll be presenting the latest data from our field-leading Dyno eCap 1 AAV vector for gene delivery to the eye. See you there! #ARVO2024

Dyno will be on the main stage at #SynBioBeta2024 today at 11am for a talk on how AI-driven protein design can dramatically expand the scope and impact of gene therapies, bringing life-changing treatments within reach for many more patients. We’ll see you there!

TODAY: Join Dyno CEO and founder Eric Kelsic at this year’s ASGCT Symposium to discover our latest breakthroughs in algorithmic design, and learn how Dyno’s Machine Learning methods are ushering in the future of gene delivery. #ASGCT2024 #ASGCT24

Join us today at our #ASGCT24 oral abstract presentation to learn more about how Dyno is applying AI, including our Low-shot Efficient Accelerated Performance (LEAP) technology, to speed up the discovery of AAV capsids for neuronal delivery.

Dyno is back from our tour of conferences! We covered a lot of ground at #ASGCT24 #SynBioBeta2024 and #ARVO2024, presenting on our brain and eye capsids, the importance of AI translatability, and how AI-driven protein design will dramatically expand the impact of gene therapies.

This month at Dyno, we honor the LGBTQIA+ community’s resilience and achievements. We're dedicated to fostering an inclusive workplace where everyone feels valued and empowered. Join us as we celebrate and support the LGBTQIA+ community. Happy Pride! 🏳️‍🌈 #Pride2024

It was a pleasure sharing with Benchling how efficient lab software supports us in our mission of using AI to engineer effective delivery of gene therapies to every cell, for every patient! Check out the video:

Dyno’s CEO and Founder Eric Kelsic will be giving a talk today at 5th Gene Therapy for Ophthalmic Disorders Summit, discussing latest breakthroughs in capsid engineering with Dyno eCap1, a pioneering product designed for intravitreal delivery-- we hope to see you there! 🧬

The Chardan Genetic Medicines & Cell Therapy Manufacturing Summit is this week in NYC! Dyno’s Founder & CEO Eric Kelsic will share AAV platform insights in a panel and present on how Dyno's approach to solving gene delivery aims to unlock therapeutic potential for every patient.

Tune into @biotechtv at #Benchtalk to hear Dyno’s Head of Gene Therapy Adrian Veres and Head of Stewardship Tyson Bertmaring discuss how Dyno solves the gene delivery challenge for our partners through our partner-centric business model and AI-driven capsid design expertise!